Adipose tissue dysregulation, a hallmark of obesity, contributes to a chronic state of low-grade inflammation and is associated with increased risk and progression of several breast cancer subtypes, including claudin-low breast tumors. Unfortunately, mechanistic targets for breaking the links between obesity-associated adipose tissue dysfunction, inflammation, and claudin-low breast cancer growth have not been elucidated. Ovariectomized female C57BL/6 mice were randomized (n = 15/group) to receive a control diet, a diet-induced obesity (DIO) diet, or a DIO + resveratrol (0.5% wt/wt) diet. Mice consumed these diets ad libitum throughout study and after 6 weeks were orthotopically injected with M-Wnt murine mammary tumor cells, a model of estrogen receptor (ER)-negative claudin-low breast cancer. Compared with controls, DIO mice displayed adipose dysregulation and metabolic perturbations including increased mammary adipocyte size, cyclooxygenase-2 (COX-2) expression, inflammatory eicosanoid levels, macrophage infiltration, and prevalence of crown-like structures (CLS). DIO mice (relative to controls) also had increased systemic inflammatory cytokines and decreased adipocyte expression of peroxisome proliferator-activated receptor gamma (PPARγ) and other adipogenesis-regulating genes.
The prevalence of obesity, an established risk and prognostic factor for several subtypes of breast cancer, has increased dramatically in the US and globally over the past 35 years. 1 Obese, relative to normoweight, postmenopausal women with estrogen receptor (ER)-negative breast cancer are more likely to have poorer response to treatment and higher rates of recurrence. 2 The ER-negative claudin-low subtype of breast cancer, which is energy balance-responsive in humans and mice and often confers a poor prognosis due to a current lack of targeted therapies. 3, 4 While obesity-associated inflammation is implicated in the generally poor response to therapy and increase in mortality in obese women compared with their lean counterparts, the mechanism by which inflammation promotes ER-negative claudin-low breast cancer growth is unknown. 5, 6 Chronic positive energy balance in obesity results in the remodeling of the adipose microenvironment and results in hypertrophic adipocytes. Studies of C57BL/6 mice have established strong correlations between fat pad mass and mean adipocyte size, a measure of hypertrophy. 7 Furthermore, with increasing adipocyte size the adipocyte secretome is enriched in pro-inflammatory adipokines and cytokines, including tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6). 8 Adipocyte size also positively correlates with macrophage infiltration in the adipose tissue as well as systemic insulin resistance. 9 ,10 TNF-α is a potent inhibitor of adipogenesis and can prevent preadipocytes from differentiating into mature adipocytes.
Partially transdifferentiated preadipocytes can possess a macrophagelike phenotype and secrete cytokines similar to macrophages. 11 Isakson et al harvested preadipocytes from obese and non-obese adipose tissue biopsies and found that the number of preadipocytes that differentiated into adipose cells was negatively correlated with both BMI and adipocyte cell size of the donors. 12 The crosstalk between hypertrophied adipocytes and macrophages promote and sustain a pro-inflammatory environment in peroxisome proliferator-activated receptor gamma (PPARγ), 13 a transcription factor regulating adipocyte differentiation and maintenance of insulin sensitivity. A higher ratio of PPARγ to COX-2, as achieved by COX-2 inhibition via non-steroidal anti-inflammatory drugs (NSAIDs) or PPARγ-agonists such as thiazolidinediones (TZD), decreases macrophage infiltration and improves insulin sensitivity as manifested by adipocyte glucose uptake. [14] [15] [16] Although not well studied in the context of cancer, pharmacologic strategies that have been successful in resolving obesity-associated inflammation in diabetes were dependent on restoring adipogenesis and adipocyte turnover. 17, 18 Resveratrol is a natural polyphenolic compound produced in several species of plants in response to pathogens. 19 Resveratrol supplementation increases PPARγ expression in vivo in the adipose tissue of obese mice and in vitro in cultured macrophages and cancer cells. [20] [21] [22] Furthermore, resveratrol has demonstrated potential as a cancer chemopreventive agent due to its established ability to attenuate the pro-inflammatory effects of obesity. 23, 24 Specifically, resveratrol decreases TNF-α production, 25 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation 26 and COX-2 activity, 27, 28 targets critical to perpetuating the cancer-promoting effects of adipose dysfunction in obesity.
The present study evaluated the ability of resveratrol to offset the effects of obesity on adipose tissue dysfunction, inflammation, and claudin-low breast cancer growth. We and others have demonstrated success in disrupting the obesity-cancer link in a variety of cancer types by targeting inflammation with omega-3 fatty acids, NSAIDs or selective COX-2 inhibitors. [29] [30] [31] Here we hypothesized that resveratrol, via its ability to prevent adipose tissue remodeling and inhibit proinflammatory cytokine production, would protect against the protumorigenic effects of obesity in our murine model of claudin-low breast cancer.
| MATERIALS AND METHODS

| In vivo studies
All animal studies and procedures were approved and monitored by the University of Texas Institutional Animal Care and Use
Committee. As summarized in Figure 1A 
| Quantitative magnetic resonance analysis
Body composition was measured on all mice at end of study by quantitative magnetic resonance (qMR) (Echo Medical Systems, Houston, TX). Measurements included lean mass, fat mass, and total water mass. Percent body fat was calculated by dividing fat mass by total body weight.
| Serum hormone, adipokine, and cytokine measurement
After 5 weeks on diet, blood was collected from mice fasted 4-6 h by retro-orbital bleed, allowed to clot for 30 m at room temperature, and serum was collected and flash frozen for subsequent analyses. Insulin and leptin were measured using mouse adipokine LINCOplex®Multi-plex Assays (Millipore, Inc., Billerica, MA). Insulin-like growth factor 1 (IGF-1) concentrations were measured using a Millipore Milliplex Rat/ Mouse IGF-1 Single Plex Assay. Adiponectin concentrations were measured using a Milliplex Mouse Adiponectin Single Plex (Millipore, Inc.). Serum concentrations of mouse cytokines, including IL-1β, IL-6, IL-10, IL-17A, interferon-γ (IFN-γ), TNF-α, and MCP-1, were measured using a Bio-Plex Pro™ Mouse Cytokine 7-Plex Assay (Bio-Rad, Inc., Hercules, CA). All assays were completed and analyzed on a Bio-Rad
Bio-Plex 200 analysis system (Bio-Rad, Inc., Hercules, CA).
| Histopathology and immunohistochemical staining
Paraffin-embedded mammary and tumor tissue were cut into 4 µm thick sections for either hematoxylin and eosin (H&E) staining or immunohistochemical analysis. Slides were deparaffinized and processed as previously described. 32 Mammary tissues were stained FIGURE 1 Resveratrol supplementation does not impact the establishment of diet induced obesity (A) Study design. B, The DIO and control regimens effectively generated obese and normal weight phenotypes, with significant differences in body weight, beginning after three weeks on diet (DIO vs control, P < 0.0001; DIO + resveratrol vs control P < 0.05; DIO vs DIO + resveratrol NS). After 6 weeks on diet and when mammary tumor cells were injected, DIO and DIO + resveratrol had significantly greater body weights than control mice (DIO vs control, P < 0.0001; DIO + resveratrol vs control P < 0.0001; DIO vs DIO + resveratrol NS). C, Percent body fat, obtained at end of study, was significantly lower in control mice vs both DIO (P < 0.0001) and DIO + resveratrol (P < 0.0001), with no differences between DIO and DIO + resveratrol mice. 
| Eicosanoid analysis
Eicosanoids in the mammary adipose tissues were extracted and analyzed by liquid chromatography/tandem mass spectroscopy (LC/ MS/MS) using the modified method described previously. 33 LC/MS/ MS analyses were performed using an Agilent 6460 Triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200 binary pump high-performance liquid chromatography (HPLC) system as described previously. 34 
| Adipogenesis PCR array
RNA was extracted from the mammary fat pad of control, DIO, and DIO + resveratrol mice (n = 6/group, randomly selected) as described above.
RNA was reverse transcribed using a cDNA conversion kit according to the analysis web portal at http://www.qiagen.com/geneglobe and fold change/ regulation was calculated using the delta delta C T method.
| Tissue resveratrol analysis
One milliliter of an extraction solvent consisting of 20% 0.1 M Sodium Acetate buffer (pH 3.8) and 80% methanol was added to each tissue sample designated for analysis. Piceatannol (Sigma) was added to the samples as an internal standard to a final concentration of 0.5 μg/mL.
The sample was disrupted using a sonic dismembrator for 1 min, then centrifuged at 10 000g for 10 min. An aliquot of 600 μL was taken from the supernatant and dried using a Speed-Vac system. The samples were then resuspended in 100 μL of the mobile phase which consisted of 25% methanol, 10% acetonitrile, and 1% acetic acid in distilled water and aliquots were injected into a Waters Acquity UPLC H-Class (Waters Corporation, Milford, MA). Analysis was accomplished using the peak area of the fluorescence response of resveratrol and piceatannol, with the lower limit of detection at 5 ng/mL (0.005 μg/ mL). The results are reported as an average of two technical replicates.
| Statistical analyses
A priori sample size calculations were completed to determine the required number of mice/treatment group (n = 15) to provide >90%
power to detect at least 25% differences in the primary study outcome, which is mean tumor volume between treatment groups. 35 Values are presented as group mean ± standard deviation (s.d.). For all tests, GraphPad Prism software was used (GraphPad Software Inc., La Jolla, CA), and P < 0.05 was considered statistically significant. Differences between groups in weekly body weight and calorie intake were analyzed by two-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Differences between groups in body fat percentage, serum hormones, adipokines, and cytokines were analyzed by one-way ANOVA followed by Tukey's post hoc test.
Differences between groups in adipocyte size, gene expression, CLS, immunohistochemical staining, tumor volume, and tumor adipocyte area were analyzed by one-way ANOVA followed by Tukey's post hoc test. Differences in gene expression detected using the Adipogenesis Array were calculated by Student's t-test using Qiagen data analysis web portal.
3 | RESULTS
| Resveratrol supplementation does not impact the establishment of diet-induced obesity
The DIO (alone or with resveratrol supplementation) and control regimens effectively generated obese and normoweight phenotypes,
respectively (Figures 1B and 1C). Significant differences in body weight
were observed after 3 weeks on diet and continued throughout the remainder of study between control mice and DIO mice. No statistically significant differences in body weight or calorie intake were detected between DIO and DIO + resveratrol mice throughout study. Average body weight is shown prior to tumor implantation for the first 6 weeks on diet ( Figure 1B) . DIO + resveratrol mice consumed on average 390.5 ± 40.1-675.6 ± 27.4 mg resveratrol/body weight (kg) per day (Supplementary Table S1 ). Percent body fat, obtained at end of study, was significantly lower in control mice (30.1 ± 3.6%) versus both DIO (49.3 ± 3.0%; P < 0.0001) and DIO + resveratrol mice (46.2 ± 4.7%; P < 0.0001), with no statistical differences between DIO and DIO + resveratrol mice ( Figure 1C ).
| Resveratrol supplementation protects against serum metabolic and inflammatory perturbations in DIO mice
As shown in Table 1 , DIO mice had significantly higher serum levels of insulin, IGF-1, and leptin compared with control mice (P < 0.01 for each analyte). DIO + resveratrol mice displayed intermediate levels of insulin and IGF-1 that were not significantly different from DIO or control mice. Leptin was significantly increased in both DIO and DIO + resveratrol mice compared with control mice (DIO vs control P < 0.0001; DIO + resveratrol vs control P < 0.0001). No differences in serum adiponectin levels were detected between groups, but control mice on average had a significantly lower leptin to adiponectin ratio compared with DIO and DIO + resveratrol mice (Table 1) .
Furthermore, DIO mice, relative to control mice, had significantly Figures 2B and 2E ). All statistical differences were at P < 0.0001. These findings on dietdependent effects on adipocyte area provide additional support that the DIO mice possessed hypertrophied adipocytes, and supplementation of the DIO diet with resveratrol inhibited the pathogenic increase in adipocyte size.
FIGURE 2
Resveratrol prevents adipocyte hypertrophy in the mammary fat pad of DIO mice. A, Representative image of H&E stained sections of the mammary fat pads from control, DIO and DIO + resveratrol mice. B, Histogram distribution (10th, 50th, and 90th percentiles) of the adipocyte areas of mammary fat pad sections from control, DIO and DIO + resveratrol. Red dashed lines indicate the median of each percentile. DIO mice had significantly higher adipocyte area for the (C) 10th percentile compared to both control and DIO + resveratrol (DIO vs control P < 0.0001; DIO vs DIO + resveratrol P < 0.0001; control vs DIO + resveratrol NS). DIO mice had significantly higher adipocyte area for the (D) 50th percentile compared to control and DIO + resveratrol (DIO vs control P < 0.0001; DIO vs DIO + resveratrol P < 0.0001). However, DIO + resveratrol mice also had significantly higher adipocyte area for the 50th percentile compared to control (P < 0.05). Similarly, DIO mice had significantly higher adipocyte area for the 90th percentile compared to control and DIO + resveratrol (DIO vs control P < 0.0001; DIO vs DIO + resveratrol P < 0.0001). Additionally, DIO + resveratrol mice also had significantly higher adipocyte area for the 90th percentile compared to control (P < 0.0001). Data presented as mean ± s.d Differences in significance denoted by different letters (a,b), NS = not significant
We measured gene expression in the mammary fat pad of mice for mediators of inflammation and genes implicated in macrophage recruitment, proliferation, and secretory products of activated macrophages. DIO mice had significantly increased gene expression of the pro-inflammatory mediators IL-6 compared with control and DIO + resveratrol mice (DIO vs control P < 0.01; DIO vs DIO + resveratrol P < 0.05) and Saa3 (DIO vs control P < 0.01; DIO vs DIO + resveratrol P < 0.01; Figure 3A ). DIO mice displayed increased gene expression of MCP-1 (P < 0.05) compared with DIO + resveratrol, but not control mice. CXCL12 expression was increased in DIO mice compared with both control (P < 0.01) and DIO + resveratrol (P < 0.01; Figure 3B ). DIO mice, relative to control mice and DIO + resveratrol mice, also displayed increased expression of GM-CSF (DIO vs control P < 0.01; DIO vs DIO + resveratrol P < 0.01) and M-CSF (DIO vs control P < 0.05; DIO vs DIO + resveratrol P < 0.01; Figure 3C ), which promote macrophage proliferation. Gene expression of TNF-α and MIF, which are both predominantly secreted by macrophages in the adipose tissue, were significantly increased in DIO mice compared with control mice (P < 0.01; P < 0.05, respectively) and DIO + resveratrol mice (P < 0.01; P < 0.01, respectively; Figure 3D ).
3 Figures 4A and 4B ). Gene expression of Emr1, which is specific to macrophages, was also increased in DIO mice compared to both control (P < 0.05) and DIO + resveratrol (P < 0.05; Figure 4C ).
We also quantified COX-2 protein expression using immunohistochemistry analysis on formalin-fixed, paraffin-embedded tissue from the mammary fat pads of mice fed the control, DIO, and DIO + resveratrol diets. DIO mice displayed approximately a two-fold increase in COX-2 protein expression relative to control (P < 0.0001) and DIO + resveratrol mice (P < 0.0001;
Figures 4A and 4D).
FIGURE 3
Resveratrol protects against inflammatory and macrophage gene signaling in DIO mice. DIO mice had significantly increased gene expression of the pro-inflammatory mediators (A) IL-6 and Saa3 relative to both control and DIO + resveratrol mice. DIO mice also had significantly increased gene expression of (B) macrophage signaling molecules MCP-1 and CXCL12 compared to DIO + resveratrol mice. DIO mice had significantly increased expression of DIO mice had significantly increased gene expression of (C) GM-CSF and M-CSF, which promote macrophage proliferation, compared to both control and DIO + resveratrol mice. Gene expression of secretory products of activated macrophages, including (D) TNF-α and MIF were significantly increased in DIO mice compared to both control and DIO + resveratrol mice. Data presented as mean ± s.d Differences in significance denoted by different letters (a,b), NS = not significant.
| Resveratrol modulates mammary tissue levels of eicosanoids and other inflammatory lipid derivatives in DIO mice
To test if modulation of COX-2 expression in the mammary fat pad resulted in corresponding effects in levels of downstream metabolites, we analyzed the mammary fat pad from four randomly selected mice/ group for levels of inflammatory lipid derivatives. DIO mice had significantly increased levels of arachidonic acid (AA) pro-inflammatory mediators PGF 2α (P < 0.05 vs control; P < 0.05 vs DIO + resveratrol), PGE 2 (P < 0.05 vs control; P < 0.05 vs DIO + resveratrol), 13,14- 
| Resveratrol maintains mammary tissue PPARγ expression in DIO mice
COX-2 metabolites PGF 2α and PGE 2 are known to inhibit PPARγ, a key regulator of adipogenesis, 13 and these interactions could explain the differences in adipocyte size observed between DIO and DIO + resveratrol mice despite both groups having equivalent body fat percentage. Accordingly, we performed immunohistochemistry analysis on paraffin-embedded mammary tissue for protein levels of PPARγ.
Relative to DIO mice, control and DIO + resveratrol mice had significantly increased staining of positive nuclei for PPARγ in the mammary fat pad (DIO vs control P < 0.0001; DIO vs DIO + resveratrol P < 0.0001; Figures 5A and 5B). Furthermore, DIO mice had significantly decreased PPARγ gene expression compared with
FIGURE 4
Resveratrol blunts mammary gland crown-like structure formation and COX-2 protein expression in DIO mice. A, Representative images of CLS and COX-2 protein expression in the mammary fat pads of control, DIO and DIO + resveratrol mice (n = 14-15/ group). B, The prevalence of CLS (expressed as CLS/area of tissue in cm 2 ) in the mammary fad pads was significantly increased in DIO mice relative to control and DIO + resveratrol mice (DIO vs control P <0.01; DIO vs DIO + resveratrol P < 0.05; control vs DIO + resveratrol NS). C, Gene expression of Emr1, a macrophage-specific marker, was significantly increased in DIO mice compared with control and DIO + resveratrol mice. D, COX-2 protein expression was significantly increased in DIO mice compared with both control and DIO + resveratrol mice (DIO vs control P <0.0001; DIO vs DIO + resveratrol P < 0.0001; control vs DIO + resveratrol NS). Data presented as mean ± s.d. Differences in significance denoted by different letters (a,b), NS = not significant 
| Resveratrol protects against obesity-induced dysregulated expression of adipogenesis-related genes in DIO mice
To further characterize the effects of maintained PPARγ expression in DIO + resveratrol mice, we performed a quantitative real-time Adipogenesis PCR array on mammary fat pad tissue for genes involved in preadipocyte commitment, differentiation and adipocyte maturation.
Differential expression data ( Figure 6 and Supplementary Table S2) demonstrate that DIO mice display patterns of decreased gene expression of targets across the spectrum of adipogenesis compared with control and DIO + resveratrol mice. Furthermore, DIO + resveratrol mice displayed a unique increase in expression of genes implicated in the beiging of adipocytes, relative to both control and DIO mice. P < 0.01; Figure 7A ). Similarly, the ex vivo tumor weight was significantly greater in DIO mice (0.50 ± 0.13 g) compared to DIO + resveratrol (0.35 ± 0.14 g; P < 0.05) and control (0.26 ± 0.16 g; P < 0.001; Figure 7B ). Furthermore, both measurements of tumor size in DIO + resveratrol mice did not statistically differ from the corresponding measurement in control mice ( Figure 7A and 7B) . We 
| DISCUSSION
We report that resveratrol supplementation prevents obesity-induced adipose tissue dysfunction, chiefly adipocyte hypertrophy, and reduces tumor growth in obese mice orthotopically transplanted with an aggressive claudin-low subtype of breast cancer. The anticancer effects of resveratrol in DIO mice were associated with:
(1) smaller mammary adipocyte size; (2) lower expression of genes
FIGURE 6
Resveratrol protects against obesity-induced dysregulated expression of genes involved in adipogenesis in DIO mice. Quantitative real-time Adipogenesis PCR array on mammary fat pad tissue for genes involved in preadipocyte commitment, differentiation, adipocyte maturation, and adipocyte beiging. Heatmap representation of log 2 fold change (log 2 (experimental group) − log 2 (average of all groups)) of control, DIO and DIO + resveratrol mice (n = 4-5/group). Black indicates a log 2 fold change of zero, representing a lack of change between the experimental group and the the average of all groups. Increasing brightness of green indicates an increase in expression (log 2 fold change>0). Increasing brightness of red indicates a lower level of the expression in the experimental group in comparison to the average of all groups (log 2 fold change <0).
(normalized to control levels) involved in promoting inflammation, macrophage recruitment, and signaling; (3) decreased mammary CLS; measures of insulin sensitivity and adipose tissue inflammation to levels comparable to lean, metabolically healthy counterparts. 25, 38, 39 Furthermore, the anticancer benefits we observed on claudin-low mammary tumor growth are consistent with findings investigating the effects of resveratrol in lung, skin, ovarian, colon, and prostate cancer studies. [40] [41] [42] [43] [44] [45] The observation that resveratrol exerts potent anticancer effects in obese mice supports the hypothesis suggested by several reports that resveratrol primarily exerts beneficial effects in the face of metabolic perturbations or inflammation (as occurs with obesity). For
FIGURE 7
Resveratrol protects against enhanced M-Wnt murine mammary tumor size, infiltrating adipocyte size, and tumor associated macrophages in DIO mice. A, DIO mice had significantly increased ex vivo tumor volume compared to DIO + resveratrol (P < 0.01) and control (P < 0.0001). Similarly, the ex vivo tumor weight (B) was significantly greater in DIO mice compared to DIO + resveratrol (P < 0.05) and control (P < 0.001). C, The median area of intratumoral adipocytes in tumors from DIO mice was significantly increased compared to both control (P < 0.001) and DIO + resveratrol (P < 0.0001). D, DIO mice had significantly higher Macrophage marker (RM0029-11H3) compared with control (P < 0.01) and DIO + resveratrol mice (P < 0.01). The abundance of (E) F4/80 positive staining was significantly higher in DIO mice compared with control (P < 0.01) and DIO + resveratrol mice (P < 0.01). but not under normal conditions in wild-type mice. 47 One apparent exception to the notion that resveratrol exerts anticancer effects primarily in the context of a pro-inflammatory state is from a DMBAinduced mammary carcinogenesis study in which resveratrol enhanced cell-mediated immune response and apoptosis and reduced epithelial carcinogenesis in lean mice. 48 However, even though the mice in the Yusuf et al study were lean, they still may have had inflammatory or metabolic pertubations, as topical DMBA treatment is well known to increase cutaneous oxidative stress and inflammation regardless of body weight or adiposity. 28, 42, 48 Inflammation varying doses and found that resveratrol treatment at physiologically relevant levels (1 and 10 µM) enhanced 3T3-L1 adipocyte differentiation while doses above 10 µM resveratrol induced cell death. 53 Other groups have shown that deleterious levels of TNF-α, prevalent in obesity, can stimulate the dedifferentiation of adipocytes, which delipidate and take on a fibroblast-like phenotype and lack the ability to respond to insulin and store triglyceride. 54 The apparent dosedependent effects on preadipocyte fate is supported by several reports showing that resveratrol at high concentrations inhibits PPARγ expression, adipocyte differentiation, and adipocyte viability in vitro. [55] [56] [57] In addition to impacting preadipocyte fate, resveratrol has also been shown to inhibit breast cancer stem cell proliferation by FIGURE 8 Proposed mechanism of the anticancer effects of resveratrol in DIO mice. Highlighted aspects of the proposed mechanism of the anticancer effects of resveratrol. DIO results in abnormal adipocyte expansion, which leads to upregulated expression of pro-inflammatory mediators, enhanced macrophage signaling, increased prevalence of CLS, increased COX-2 expression, and decreased expression of proadipogenic genes such as PPARγ. This adipocyte reprogramming is associated with larger tumors, larger intratumoral adipocytes and a high abundance of tumor-associated macrophages. Supplementation of DIO mice with resveratrol attenuates many of the pro-cancer effects of DIO suppressing the Wnt/β-Catenin signaling pathway, which is involved in tumor growth and metastasis and can also regulate adipogenesis. 58 We report here that supplementation of resveratrol in the diet (0.5% wt/wt) resulted in an average intake/kg body weight/day of 500.4 ± 100.1 mg/kg/day, which is in the upper half of the range of doses shown to have anticancer effects in multiple preclinical cancer studies. 38, 43, 59 We found that this pharmacologic level of resveratrol supplementation in DIO + resveratrol mice relative to DIO mice did not impact body weight or body fat percentage, but did impart considerable protection against obesity-associated inflammation.
Preventing adipocyte hypertrophy and the associated shift in pro- during pregnancy. 62 Resveratrol also induced adipose browning in rats when added to an obesogenic diet. 63 There were several limitations to our study. First, we attempted to measure levels of resveratrol in the serum of fasted mice, but had few samples pass the threshold of detection, which was likely due to resveratrol being largely cleared from the blood in the mice analyzed.
Thus, we are unable to report the serum levels that our dose achieved.
However, we were successful in measuring resveratrol levels in tumors samples and found a range from 157.7 nmol/g to 661.5 nmol/g (Supplementary Table S3 ). This is comparable to the levels in the murine prostate reported by Narayanan et al that range from 175.2 nmol/g to 416.2 nmol/g. 45 To our knowledge tissue resveratrol concentrations in human tumors following resveratrol supplementation have not been widely reported so we unfortunately cannot compare the levels observed in our preclinical study to human studies.
Another limitation of our study is the lack of a normal weight control group supplemented with resveratrol, which could have more clearly delineated the effects (if any) of resveratrol in the absence of obesity.
Finally, we observed no effect of resveratrol on the gene expression of the sirtuin pathway in our study (data not shown). Sirt-1 is reportedly associated with the anticancer effects of resveratrol in vitro, although the effects of resveratrol on the sirtuin pathway are likely dose-and tissue-dependent. 64 Given the global prevalence of obesity, the emerging association between obesity and the development and progression of several breast cancer subtypes, and the current lack of targeted therapies for claudin-low and additional subtypes of triple-negative breast cancer, 
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